With a $42M raise and a reverse merger, Synlogic makes a quick flip onto Nasdaq
Jose Carlos Gutierrez-Ramos has found the back door to Nasdaq.
The CEO at Cambridge, MA-based Synlogic is executing a reverse merger with the failed Austin-based biotech Mirna Therapeutics, which will put the synthetic biology company into the public market. And in addition, the biotech says that it recently closed a $42 million C round to back its transition into the spotlight of public reporting.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
